Tiziana Life Sciences Ltd (NASDAQ:TLSA) will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on December 6th at 3:00 PM ET. Matthew Davis, COO and CMO, will discuss recent clinical updates and the Phase 2 trial of intranasal foralumab, a human anti-CD3 monoclonal antibody, targeting non-active secondary progressive multiple sclerosis and neuroinflammatory diseases. The focus extends to neurodegenerative conditions like Alzheimer’s. Interested participants can register at https://us02web.zoom.us/webinar/register/WN_9-kFpy_DQ8OlBAoDQg8D7w.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com